Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety ProfileKeyu Li, Bruce A. Keyt, Rodnie Rosete et al.|Blood|2022Cited by 10
Abstract 2959: Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanismsKeyu Li, Bruce A. Keyt, Rui Yun et al.|Cancer Research|2023Cited by 2